1 results match your criteria: "Hopital St Louis and University of Paris[Affiliation]"
Article Synopsis
- The iNTEGRATE study evaluates the safety and effectiveness of ibrutinib combined with prednisone in patients with newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD).
- Patients aged 12 and older were randomly assigned to receive either the drug combination or a placebo, and various health outcomes were monitored over 48 weeks and beyond.
- Results showed no significant differences in response rates or secondary outcomes between the two groups, indicating that ibrutinib-prednisone did not provide a clear advantage over placebo-prednisone in treating cGVHD.